We identified MGMT promoter hypermethylation not only in samples from patients with MS and PML, but also in those with metabolic and degenerative diseases, such as EPM, CPM and Wallerian degeneration (Table 1, Figure 1). Here, PML is linked to myeloid sarcoma.